{"entity":{"id":"fabrice-barlesi","kind":"person","name":"Fabrice Barlesi","aka":[],"tldr":"Fabrice Barlesi runs Europe's largest cancer centre and is a leading lung cancer trialist.","summary":"Fabrice Barlesi is Director General of Gustave Roussy and a thoracic oncologist, having previously led thoracic oncology in Marseille. His specialisms are thoracic oncology, immunotherapy, precision medicine and cancer centre leadership. He runs Europe's largest cancer centre and is a leading lung cancer trialist whose research covers immune checkpoint inhibitors and targeted therapy in non-small-cell lung cancer. He was the founding coordinator of several French national lung cancer trial programmes, and his Lancet paper on Biomarkers France reported a nationwide programme of routine molecular profiling for patients with advanced non-small-cell lung cancer. His Gustave Roussy profile and PubMed listing are linked.","asOf":"2026-09-08","links":[{"label":"Gustave Roussy","url":"https://www.gustaveroussy.fr/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barlesi%20F%5BAuthor%5D%20lung"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General, Gustave Roussy; thoracic oncologist","institutionId":"gustave-roussy","specialisms":["Thoracic oncology","Immunotherapy","Precision medicine","Cancer centre leadership"],"profiles":[{"label":"Gustave Roussy","url":"https://www.gustaveroussy.fr/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barlesi%20F%5BAuthor%5D%20lung"}],"papers":[{"title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme (Biomarkers France)","journal":"Lancet","year":2016,"doi":"10.1016/S0140-6736(16)00004-0"}]},"route":"/people/fabrice-barlesi/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"institution":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"}],"paper":[{"id":"paper-krystal-12-plain-language-summary-future-oncol-2026","kind":"paper","name":"KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations","route":"/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/"}],"company":[{"id":"ifct","kind":"company","name":"Intergroupe Francophone de Cancérologie Thoracique","route":"/companies/ifct/"}]}}